Background and Aim: With increased awareness of late-onset type 1 diabetes and the importance of accurate diabetes classification, there is a need to reassess the epidemiological and clinical characteristics of people with T1D (PwT1D). We report analyses of a novel population based cohort of PwT1D in Israel.
Methods: Using database of Clalit HMO in Israel, insuring 4.8M people (51.5% of the population) we established a registry of all PwT1D. Prevalence, annual incidence, assessment of anthropometric, metabolic parameters, complications, and comorbidities were analyzed.
Results: We recorded data of 13,167 PwT1D (0.27% of the population, 51.3% men), with an annual incidence of 1.05/10,000 people representing a 13% increase over the past decade. Median age at diagnosis is 22 years with 25% diagnosed at age ≥40 years. Median age of current PwT1D is 36 years with 25% are ≥55. Of note, 50% are either overweight or obese, with over 50% having metabolic abnormalities, traditionally associated with type 2 diabetes. Hypothyroidism (16.1%) and Celiac disease (4.5%) are the most prevalent autoimmune diseases in this cohort. Additional characteristics are depicted in table 1.
Conclusion: Currently, a significant proportion of PwT1D are middle aged or older, half are overweight or obese with the majority having additional characteristics of the metabolic syndrome. Efforts for accurate classification of PwT1D and addressing associated comorbidities are of key importance.
H.Duskin-bitan: None. A.Tirosh: Advisory Panel; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company, Research Support; Medtronic, Sanofi, Speaker's Bureau; Medtronic, Novo Nordisk, Sanofi, Eli Lilly and Company. T.Beckenstein: None. D.Netzer: None. R.Arbel: None. A.Peretz: None.
